WILMINGTON, Del. / Aug 15, 2023 / Business Wire / On July 13, 2023, Phreesia, Inc.’s (“Phreesia”) Board of Directors approved the grant of restricted stock unit awards pursuant to Phreesia’s 2023 Inducement Award Plan (the “Plan”). On August 15, 2023, Phreesia made grants pursuant to the Plan in an aggregate amount of 12,285 shares of its common stock to 24 new non-executive employees to induce them to join Phreesia. The awards vest annually in equal installments over a four-year period following their grant, subject to continued employment. Each award was granted as a material inducement to employment in accordance with the NYSE Listed Company Manual Rule 303A.08.
About Phreesia
Phreesia is the trusted leader in patient activation, giving providers, health plans, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled more than 120 million patient visits in 2022–more than 1 in 10 visits across the U.S.–scale that we believe allows us to make meaningful impact. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives efficiency and improves healthcare outcomes. To learn more, visit www.phreesia.com.
Last Trade: | US$31.66 |
Daily Change: | -0.89 -2.73 |
Daily Volume: | 677,648 |
Market Cap: | US$1.880B |
May 28, 2025 March 12, 2025 December 09, 2024 October 28, 2024 October 01, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load